Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $30.27 Average Target Price from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has earned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $30.2727.

Several research firms have recently commented on BCAX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Bank of America started coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target on the stock. Morgan Stanley upped their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Guggenheim started coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th.

Bicara Therapeutics Trading Down 1.7%

Bicara Therapeutics stock opened at $20.21 on Thursday. The stock has a market cap of $1.33 billion, a P/E ratio of -7.27 and a beta of -0.53. The stock has a 50 day moving average of $21.64 and a 200-day moving average of $18.89. Bicara Therapeutics has a 52 week low of $8.48 and a 52 week high of $24.25.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). As a group, equities analysts predict that Bicara Therapeutics will post -3.48 earnings per share for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 12,500 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00. Following the sale, the chief operating officer directly owned 191,641 shares of the company’s stock, valued at approximately $3,888,395.89. This represents a 6.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $23.61, for a total value of $354,150.00. Following the sale, the chief executive officer directly owned 362,152 shares in the company, valued at approximately $8,550,408.72. This represents a 3.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 100,600 shares of company stock valued at $2,119,199. 13.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BCAX. AQR Capital Management LLC bought a new stake in Bicara Therapeutics in the first quarter valued at $248,000. Woodline Partners LP lifted its stake in Bicara Therapeutics by 26.5% in the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock valued at $4,543,000 after buying an additional 72,998 shares during the last quarter. Geode Capital Management LLC lifted its stake in Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock valued at $6,248,000 after buying an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Bicara Therapeutics by 26.0% in the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock valued at $255,000 after buying an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.